| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2008PNAS..10515281L |
| P356 | DOI | 10.1073/PNAS.0804678105 |
| P932 | PMC publication ID | 2563066 |
| P698 | PubMed publication ID | 18829439 |
| P5875 | ResearchGate publication ID | 23294102 |
| P2093 | author name string | John R Yates | |
| Tao Xu | |||
| Sung Kyu Park | |||
| Lujian Liao | |||
| Peter Vanderklish | |||
| P2860 | cites work | Gene expression profiles in a transgenic animal model of fragile X syndrome | Q38362679 |
| Graded regulation of the Kv2.1 potassium channel by variable phosphorylation. | Q40242350 | ||
| Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory | Q42623917 | ||
| Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation | Q42811953 | ||
| Rapid recruitment of NMDA receptor transport packets to nascent synapses. | Q44044943 | ||
| RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice | Q48392342 | ||
| Status epilepticus in a patient with fragile X syndrome: electro-clinical features and peri-ictal neuroimaging | Q48417121 | ||
| Functional and quantitative proteomics using SILAC | Q57369727 | ||
| Fragile X syndrome | Q69911964 | ||
| Comparing phenotypes in patients with idiopathic autism to patients with velocardiofacial syndrome (22q11 DS) with and without autism | Q81442941 | ||
| Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the Type-1 plasminogen activator inhibitor mRNA | Q24290299 | ||
| A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling | Q24294449 | ||
| LINE-1 ORF1 protein localizes in stress granules with other RNA-binding proteins, including components of RNA interference RNA-induced silencing complex | Q24309597 | ||
| Identification of a new human catenin gene family member (ARVCF) from the region deleted in velo-cardio-facial syndrome | Q24317602 | ||
| Experimental observations on the development of polarity by hippocampal neurons in culture | Q24679532 | ||
| GoMiner: a resource for biological interpretation of genomic and proteomic data | Q24796534 | ||
| Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics | Q28131742 | ||
| Large-scale analysis of the yeast proteome by multidimensional protein identification technology | Q28131778 | ||
| A decade of molecular studies of fragile X syndrome | Q28203140 | ||
| BMS-204352: a potassium channel opener developed for the treatment of stroke | Q28217424 | ||
| Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome | Q28512868 | ||
| Presynaptic Ca2+-activated K+ channels in glutamatergic hippocampal terminals and their role in spike repolarization and regulation of transmitter release | Q28573459 | ||
| Rapid, activity-induced increase in tissue plasminogen activator is mediated by metabotropic glutamate receptor-dependent mRNA translation | Q28579381 | ||
| The mGluR theory of fragile X mental retardation | Q29615060 | ||
| Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function | Q29616372 | ||
| Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome | Q29616495 | ||
| Dynamics of protein turnover, a missing dimension in proteomics | Q30862513 | ||
| Proteome dynamics in complex organisms: using stable isotopes to monitor individual protein turnover rates. | Q31138528 | ||
| Dendritic spine structural anomalies in fragile-X mental retardation syndrome | Q33919487 | ||
| Association of a functional deficit of the BKCa channel, a synaptic regulator of neuronal excitability, with autism and mental retardation | Q34562461 | ||
| Phosphoproteomic analysis of Her2/neu signaling and inhibition | Q34772747 | ||
| Mass spectrometric-based approaches in quantitative proteomics | Q35073565 | ||
| Identification of fodrin as a major calmodulin-binding protein in postsynaptic density preparations | Q36206759 | ||
| Differential translation and fragile X syndrome | Q36228095 | ||
| Lessons from fragile X regarding neurobiology, autism, and neurodegeneration | Q36411069 | ||
| Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond. | Q36528275 | ||
| Stable isotopic labeling by amino acids in cultured primary neurons: application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signaling | Q36713646 | ||
| 15N metabolic labeling of mammalian tissue with slow protein turnover | Q36857384 | ||
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | knockout mouse | Q1364740 |
| P304 | page(s) | 15281-15286 | |
| P577 | publication date | 2008-09-30 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice | |
| P478 | volume | 105 |
| Q30458503 | 15N-labeled brain enables quantification of proteome and phosphoproteome in cultured primary neurons |
| Q36533991 | A chemical proteomic atlas of brain serine hydrolases identifies cell type-specific pathways regulating neuroinflammation |
| Q42418615 | A computational approach to correct arginine-to-proline conversion in quantitative proteomics |
| Q33958687 | A genetic engineering solution to the "arginine conversion problem" in stable isotope labeling by amino acids in cell culture (SILAC). |
| Q48244382 | Abnormal presynaptic short-term plasticity and information processing in a mouse model of fragile X syndrome |
| Q33638957 | Activity-dependent regulation of release probability at excitatory hippocampal synapses: a crucial role of fragile X mental retardation protein in neurotransmission |
| Q38393817 | Acute synthesis of CPEB is required for plasticity of visual avoidance behavior in Xenopus |
| Q47255421 | Alterations in CA1 hippocampal synapses in a mouse model of fragile X syndrome. |
| Q26796317 | Altered Neuronal and Circuit Excitability in Fragile X Syndrome. |
| Q64120167 | Altered steady state and activity-dependent de novo protein expression in fragile X syndrome |
| Q38453391 | Analysis of Signaling Endosome Composition and Dynamics Using SILAC in Embryonic Stem Cell-Derived Neurons |
| Q30418368 | Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model. |
| Q37581410 | Applying mass spectrometry-based proteomics to genetics, genomics and network biology |
| Q26786427 | Approaches for targeted proteomics and its potential applications in neuroscience |
| Q26852070 | Astrocytes conspire with neurons during progression of neurological disease |
| Q43119646 | Astrocytes prevent abnormal neuronal development in the fragile x mouse. |
| Q38259780 | Autism spectrum disorder: an omics perspective |
| Q28910185 | CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation |
| Q41312671 | Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome |
| Q38395256 | Characterization of a SILAC method for proteomic analysis of primary rat microglia |
| Q37627065 | Commentary: Depletion of the Fragile X Mental Retardation Protein in Embryonic Stem Cells Alters the Kinetics of Neurogenesis |
| Q37626883 | Comparing cellular proteomes by mass spectrometry |
| Q24613296 | Conceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndrome |
| Q50641997 | De Novo and Uninterrupted SILAC Labeling of Primary Microglia. |
| Q41073215 | Developing BACE-1 inhibitors for FXS. |
| Q33605287 | Dual-pressure linear ion trap mass spectrometer improving the analysis of complex protein mixtures |
| Q26782616 | Dysregulation and restoration of translational homeostasis in fragile X syndrome |
| Q92126951 | Emerging proteomic approaches to identify the underlying pathophysiology of neurodevelopmental and neurodegenerative disorders |
| Q30536899 | FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels |
| Q36008447 | Fmr1 deficiency promotes age-dependent alterations in the cortical synaptic proteome. |
| Q57156403 | Fragile X and APP: a Decade in Review, a Vision for the Future |
| Q48915976 | Fragile X mental retardation protein controls ion channel expression and activity. |
| Q30502814 | Fragile X mental retardation protein is required for programmed cell death and clearance of developmentally-transient peptidergic neurons |
| Q35661582 | Fragile X syndrome: the GABAergic system and circuit dysfunction |
| Q42132724 | GABA and glutamate: the Yin and Yang of fragile X |
| Q34689960 | Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models |
| Q35492486 | Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome |
| Q28586039 | Identification and characterisation of Simiate, a novel protein linked to the fragile X syndrome |
| Q42546018 | Identification of a novel neurotrophic factor from primary retinal Müller cells using stable isotope labeling by amino acids in cell culture (SILAC). |
| Q37386040 | Identification of functional marker proteins in the mammalian growth cone. |
| Q35543947 | Impaired inhibitory control of cortical synchronization in fragile X syndrome |
| Q48343073 | Impaired presynaptic long-term potentiation in the anterior cingulate cortex of Fmr1 knock-out mice. |
| Q37577761 | Macro role(s) of microRNAs in fragile X syndrome? |
| Q92192968 | Mass Spectrometry for the Study of Autism and Neurodevelopmental Disorders |
| Q38222163 | Mass spectrometry for the study of autism and neurodevelopmental disorders |
| Q33874584 | Meeting at the crossroads: common mechanisms in Fragile X and Down syndrome |
| Q28487557 | Metabolic turnover of synaptic proteins: kinetics, interdependencies and implications for synaptic maintenance |
| Q42063025 | Molecular and genetic analysis of the Drosophila model of fragile X syndrome |
| Q37519665 | Multidimensional protein identification technology for clinical proteomic analysis |
| Q64950869 | Neuroligin 1, 2, and 3 Regulation at the Synapse: FMRP-Dependent Translation and Activity-Induced Proteolytic Cleavage. |
| Q33863167 | Neuropeptide Release is Impaired in a Mouse Model of Fragile X Mental Retardation Syndrome. |
| Q53422584 | Of Men and Mice: Modeling the Fragile X Syndrome. |
| Q34276729 | Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia |
| Q37065318 | Promiscuous or discriminating: Has the favored mRNA target of Fragile X Mental Retardation Protein been overlooked? |
| Q64121287 | Proteomic analyses reveal misregulation of LIN28 expression and delayed timing of glial differentiation in human iPS cells with MECP2 loss-of-function |
| Q40127825 | Proteomic analysis reveals CCT is a target of Fragile X mental retardation protein regulation in Drosophila |
| Q90038146 | Proteomics and pulse azidohomoalanine labeling of newly synthesized proteins: what are the potential applications? |
| Q35755401 | Proteomics of the Synapse--A Quantitative Approach to Neuronal Plasticity. |
| Q57721609 | Quantitative Proteomic Approaches in Mouse: Stable Isotope Incorporation by Metabolic (SILAC) or Chemical Labeling (Reductive Dimethylation) Combined with High-Resolution Mass Spectrometry |
| Q90428279 | Quantitative analysis of newly synthesized proteins |
| Q33697720 | Quantitative nanoproteomics for protein complexes (QNanoPX) related to estrogen transcriptional action |
| Q37833588 | Quantitative proteomics for investigating psychiatric disorders |
| Q33821949 | Quantitative proteomics in laser capture microdissected sleep nuclei from rat brain |
| Q34062438 | Quantitative proteomics of Spodoptera frugiperda cells during growth and baculovirus infection. |
| Q48376077 | Rcan1 deficiency impairs neuronal migration and causes periventricular heterotopia. |
| Q27000073 | Recent advances in quantitative neuroproteomics |
| Q35196556 | Regulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders |
| Q33855008 | Regulation of protein levels in subcellular domains through mRNA transport and localized translation |
| Q34431654 | Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule |
| Q37855556 | STDP and Mental Retardation: Dysregulation of Dendritic Excitability in Fragile X Syndrome |
| Q33891889 | Short- and long-term memory are modulated by multiple isoforms of the fragile X mental retardation protein |
| Q24652437 | Shotgun proteomics in neuroscience |
| Q34418933 | Stable isotope labeling by amino acids in cultured primary neurons |
| Q34959041 | Study of neurotrophin-3 signaling in primary cultured neurons using multiplex stable isotope labeling with amino acids in cell culture |
| Q38693916 | Synaptic vesicle dynamic changes in a model of fragile X. |
| Q59804586 | TGFβ-Signaling and FOXG1-Expression Are a Hallmark of Astrocyte Lineage Diversity in the Murine Ventral and Dorsal Forebrain |
| Q48217717 | The RNA-binding protein, ZC3H14, is required for proper poly(A) tail length control, expression of synaptic proteins, and brain function in mice. |
| Q42146983 | The effects of proteasomal inhibition on synaptic proteostasis |
| Q37359934 | The fragile X mental retardation protein in circadian rhythmicity and memory consolidation |
| Q37387721 | The state of synapses in fragile X syndrome |
| Q37976002 | To label or not to label: applications of quantitative proteomics in neuroscience research |
| Q35230774 | Visual sensorial impairments in neurodevelopmental disorders: evidence for a retinal phenotype in Fragile X Syndrome |
| Q41899899 | βCaMKII in lateral habenula mediates core symptoms of depression |
Search more.